David Chang will leave his post after an eight-year run at the cell therapy maker. Elsewhere, a next-generation blood disease drug stumbled and an acquisition yielded an FDA approval for AbbVie.
An article from
News roundup
David Chang will leave his post after an eight-year run at the cell therapy maker. Elsewhere, a next-generation blood disease drug stumbled and an acquisition yielded an FDA approval for AbbVie.
Published May 29, 2026
Getty Images
David Chang to hand over the reins at Allogene; Ex-Esperion CEO gets started at Phlow
Allogene CEO David Chang stepping down
With Elahere building steam, AbbVie nets FDA nod for another ImmunoGen cancer asset
ASCO: After Takeda’s defeat, Dizal picks up baton to take on J&J in EGFR lung cancer subtype
Five biotech news updates to stay on top of today
Charles River CEO says it likely won’t be the last manufacturer to break away from cell and gene therapy
Ahead of ASCO, all eyes on pancreatic cancer
Fierce Pharma Asia—More China biotech hawkishness; Pfizer’s $10B Innovent deal; Astellas’ roadmap
Outlook moves toward potential US nod for thrice-snubbed eye drug with FDA appeal win
Longtime Allogene CEO David Chang will be stepping down at the end of June. Chang has served as the company’s CEO for the past…
Alzheimer's drug rollout letdown, a China-based heart drug startup, and more biotech news from The Readout
Pfizer invests billions to buy Chinese drugs, WHO maps experimental response to Ebola outbreak, and other biotech news from The…
Avalo reported study success in what’s proven to be a tough-to-treat skin disease. Elsewhere, BioNTech announced plans to close…
Vinay Prasad's acting replacement, remembering genomics pioneer J. Craig Venter, and more biotech news from The Readout
As AbbVie continues to capitalize on its deal for ImmunoGen with the growth of commercial antibody-drug conjugate (ADC) Elahere,…
